European healthcare cuts benefit biologic makers

According to a recent article at Reuters, the European Pharma industry is looking to its generic segments to profit. Sanofi aventis, Merck, Teva and Astra Zeneca have all indicated that they will look to strengthen their biologics divisions. Read the full article here.

Share this article with your social network, just click below to share now!

Share |